GSK Reports Outcome from US FDA Advisory Committee Meeting on Daprodustat for Anemia of CKD

London UK October 27, 2022 -- GSK plc (LSE/NYSE: GSK) today reports that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported that the benefit of treatment with daprodustat outweighs the risks...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials